Status:
COMPLETED
A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine approximately what percentage of an orally administered dose of PD-0332991 is absorbed from the gastrointestinal tract into the systemic circulation. This app...
Eligibility Criteria
Inclusion
- Healthy male or female of non-childbearing potential between the ages of 18 and 55 years of age.
- A body mass index (BMI) between 17.5 and 30.5 kg/m2, and a total body weight greater than 50kg (110 lbs)
Exclusion
- Any condition which could possibly affect drug absorption.
- Pregnancy or actively nursing females, or females of childbearing potential.
- A positive urine drug screen.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01802476
Start Date
May 1 2013
End Date
June 1 2013
Last Update
December 17 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Nottingham, Nottinghamshire, United Kingdom, NG11 6JS